Osprey Medical announced the expansion of its portfolio with introduction of the DyeVert PLUS Contrast Modulation/Monitoring System.
This new platform integrates the current DyeVert technology with substantial patient management and monitoring capabilities.
The system has received European CE Mark and FDA clearance is pending. The Company anticipates US availability Q1 2017.
Highlighted at the Transcatheter Cardiovascular Therapeutics (“TCT”) Conference, held October 29 – November 2 in Washington DC, the DyeVert PLUS received publicity via both podium presence and considerable booth exposure.
As one of the world’s largest gatherings of heart specialists, TCT hosts over 6,000 medical professionals in the fields of interventional cardiology and vascular medicine.
Presented at TCT’s Contrast-Induced Acute Kidney Injury Forum, Professor Steffen Desch of Heart Centre – Lubeck Germany, illustrated the benefits of DyeVert PLUS. “This platform connects DyeVert’s contrast reduction capability with the means to actively manage a patient during intervention”, stated Professor Desch. “Enabling real-time contrast management allows the ability to tailor to specific patient needs.”
The DyeVe r t PLUS allows the DyeVert technology to interface through wireless communic ations with a disposable “smart syringe” and reusable LCD monitor. The proprietary system offer several key benefits:
Monitors and displays contrast dose levels to be used based on a patient’s kidney function;
Automatically provides real – time tracking of contrast injected during a procedure , allowing physicians the ability to proactively manage a patient; and
Provides a more accurate method of recording contrast dosage given to the patient.
Erlier this year, the industry – guiding Society for Cardiovascular Angiography and Interventions (SCAI) published an expert-consensus best practice update .
This communicated h eightened focus on contrast management of kidney – impaired patients , for which the DyeVe rt PLUS addresses. Aspects included minimization of contrast dose, contrast monitoring in real- time , and physicians being informed when limits (dose based on kidney function ratios) are reached.
Osprey’s President and CEO, Mike McCormick, said : “Osprey’s commercialization strategy encompasses continued technology advancement , to augment our expanding sales force with the tools to ensure sustained growth.
Given increased scrutiny of patient outcomes, the DyeVert PLUS is well situated to address new industry guidelines . We expect this system will have a strong uptake as soon as it becomes available in the US . ”